Corrigendum to “A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD” [Respir. Med. 120 November 2016 16–24] - 26/07/17

Donald P. Tashkin ^{a, ⁎} , Fernando J. Martinez ^b, Roberto Rodriguez-Roisin ^c, Charles Fogarty ^d, Mark Gotfried ^e, Michael Denenberg ^f, Gregory Gottschlich ^g, James F. Donohue ^h, Chad Orevillo ⁱ, Patrick Darken ⁱ, Earl St Rose ⁱ, Shannon Strom ^j, Tracy Fischer ^j, Michael Golden ^j, Colin Reisner ⁱ

^a David Geffen School of Medicine at UCLA, Los Angeles, CA, USA 

^b Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA 

^c Servei de Pneumologia, Institut del Tòrax, Hospital Clínic-IDIBAPS-CIBERES, University of Barcelona, Barcelona, Spain 

^d Spartanburg Medical Research, Spartanburg, SC, USA 

^e Pulmonary Associates, Phoenix, AZ, USA 

^f Clinical Research of Rock Hill, Rock Hill, SC, USA 

^g New Horizons Clinical Research, Cincinnati, OH, USA 

^h University of North Carolina School of Medicine, Chapel Hill, NC, USA 

ⁱ Pearl Therapeutics Inc., Morristown, NJ, USA 

^j Pearl Therapeutics Inc., Durham, NC, USA 

^∗Corresponding author.

Le texte complet de cet article est disponible en PDF.